Medicines Discovery Catapult's Chemical Protein Stability Assay generates vital data to support drug discovery innovators and will enhance Selvita’s screening platform.
The policy landscape for deep biotech has seen remarkable strides over the past year, positioning the UK as a leader in engineering biology innovation.
In 2035, we envision a UK biotech sector with a stronger long-term capital base supporting both early—and later-stage firms. To make Vision 2035 a reality, we, as a sector, must focus on areas that will have the greatest impact. Read the report to find out what those are!
Watch the recording to see how the BIA Regulatory and Access Community is driving UK life sciences forward through expert insights on ILAP, MHRA initiatives, and collaborative innovation.
Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research collaboration and global license agreement.
Washington’s shifting policy landscape continues to cause uncertainty, while the UK is staying calm. Join our webinar this Thursday to hear how we’re engaging with international partners and government to ensure the UK voice is heard and our sector remains robust.
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, announces a partnership with the NHS Cancer Vaccine Launch Pad (CVLP) to fast-track access for NHS patients into the fourth cohort of the Company’s Phase 2 clinical SCOPE study.
Oligos explainer: A new frontier in precision medicine, highlights the transformative potential of oligonucleotide therapies. These precision medicines, which use short DNA or RNA molecules to target specific genes, offer groundbreaking solutions for diseases previously deemed untreatable, from rare genetic disorders to cancer.
Emerson partners with biopharmaceutical companies to drive innovation, efficiency, and compliance in life sciences manufacturing through cutting-edge automation and process expertise.
Following a number of ‘firsts’ for Stablepharma during 2024, we spoke with Ozgur Tuncer, CEO and Executive Director about a year that has accelerated the commercialisation of the world’s first fridge-free vaccine, SPVX02, for the prevention of Tetanus and Diphtheria.
The 2024 Bionow Awards dinner marked an exceptional evening of recognition and celebration, as 342 distinguished guests gathered at the Concorde Conference Centre on 6 March to honour those who have demonstrated outstanding ingenuity and dedication.
